华大基因(300676) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥671,910,156.79, representing a decrease of 18.18% compared to ¥821,250,378.55 in the same period last year[2]. - The net profit attributable to shareholders was a loss of ¥52,695,120.08, a decline of 524.87% from a profit of ¥12,402,522.05 in the previous year[2]. - The net cash flow from operating activities was -¥397,093,777.71, a decrease of 422.92% compared to -¥75,937,361.58 in the same period last year[2]. - The basic earnings per share were -¥0.1278, down 521.78% from ¥0.0303 in the same period last year[2]. - The decline in performance was primarily due to a decrease in revenue scale and slower-than-expected collection of accounts receivable, leading to increased credit impairment losses compared to the previous year[10]. - Total operating revenue for the current period is ¥671,910,156.79, a decrease of 18.2% from ¥821,250,378.55 in the previous period[24]. - Net profit for the current period is a loss of ¥55,295,405.94, compared to a profit of ¥12,150,258.43 in the previous period[25]. - The basic earnings per share for the current period is -0.1278, compared to 0.0303 in the previous period, indicating a significant decline[25]. Assets and Liabilities - The total assets at the end of the reporting period were ¥12,595,327,557.05, an increase of 0.42% from ¥12,542,286,394.63 at the end of the previous year[2]. - Total liabilities increased to ¥3,360,188,917.99 from ¥3,270,676,576.56, marking a rise of 2.7%[23]. - The company’s total equity stands at ¥9,235,138,639.06, slightly up from ¥9,271,609,818.07 in the previous period[23]. - The company's total current assets amounted to RMB 6,888,220,016.77, slightly up from RMB 6,875,791,256.55 at the beginning of the period[21]. - The company's fixed assets increased to RMB 2,601,833,058.56 from RMB 2,578,695,623.85[21]. Cash Flow - The company's cash flow statement indicates a need for improved cash management strategies, as indicated by the current financial performance[27]. - Operating cash inflow for the current period was $652.49 million, down from $777.11 million in the previous period, representing a decrease of approximately 16.06%[28]. - Net cash flow from operating activities was -$397.09 million, compared to -$75.94 million in the previous period, indicating a significant decline[28]. - Cash inflow from investment activities totaled $1.84 billion, an increase from $1.08 billion in the prior period, reflecting a growth of about 70.38%[28]. - Cash inflow from financing activities was $570.96 million, a substantial increase from $32.40 million in the previous period, marking a growth of approximately 1,661.73%[29]. - The ending cash and cash equivalents balance was $2.63 billion, down from $2.91 billion in the previous period[29]. - The company experienced a negative net increase in cash and cash equivalents of -$68.26 million, compared to -$644.24 million in the previous period, indicating an improvement[29]. Shareholding Structure - As of the report date, the controlling shareholder, Huada Holdings, and its concerted parties held 147,759,217 shares, accounting for 35.53% of the total share capital[13]. - A total of 10,484 million shares held by the controlling shareholder were pledged, representing 70.95% of their holdings and 25.21% of the total share capital[13]. - Huada Holdings transferred 10.5% of its equity to a company wholly owned by the actual controller, Wang Jian, resulting in an increase in Wang Jian's direct and indirect shareholding from 31.90% to 35.75%[14]. - The overall shareholding and voting rights of Huada Holdings and its concerted parties remained unchanged at 37.34%[14]. - The company’s major shareholders include Shenzhen Huada Gene Technology Co., Ltd. with 141,285,593 shares and Shenzhen Huada San Shengyuan Technology Co., Ltd. with 34,470,455 shares[12]. - The company has not disclosed any significant changes in the shareholding structure of the top 10 shareholders due to margin trading activities[10]. - The controlling shareholder, BGI Holdings, plans to reduce its stake by up to 8,316,432 shares (2% of total share capital) from December 17, 2024, to March 16, 2025[15]. - BGI Holdings has already reduced its stake by 7,488,300 shares (1.8008% of total share capital) between March 11 and March 14, 2025[15]. - After the reduction, the combined shareholding of BGI Holdings and its concerted parties decreased from 37.34% to 35.53%, without changing the company's control[15]. Research and Development - The company reported a significant increase in research and development expenses, totaling ¥117,331,387.43, up from ¥106,372,298.63 in the previous period, reflecting a growth of 11.5%[24]. - The company has not reported any new product developments or market expansion strategies in the current period[10]. Government Subsidies - The company received government subsidies amounting to ¥2,997,389.85 during the reporting period[3]. Investment Income - The investment income increased by 374.19% to ¥3,416,203.88 from a loss of -¥1,245,924.99 in the previous year[7].